Multicenter Retrospective Study of Isoflurane in Refractory and Super-Refractory Status Epilepticus

Launched by HOPITAL OF MELUN · Apr 13, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment called Isoflurane for patients who are experiencing a severe type of seizure called refractory status epilepticus. This condition means that the seizures are not responding to standard treatments. The study aims to find out how effective Isoflurane can be when used as a third option for managing these difficult seizures.

To be eligible for this study, participants need to be adults over the age of 18 who were hospitalized in an intensive care unit (ICU) between January 1, 2016, and January 1, 2023, and received Isoflurane as part of their treatment. Unfortunately, patients who had seizures due to a lack of oxygen after a cardiac arrest or those who do not want their medical information used cannot participate. If you or someone you know meets these criteria, joining the trial could help researchers understand if Isoflurane is a useful option for treating this challenging condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \> 18 years, hospitalized in ICU between 2016-01-01 and 2023-01-01, suffering refractory status epilepticus treated by inhaled Isoflurane as third anticonvulsive therapy
• Exclusion Criteria:
• • post-anoxic refractory status epilepticus after cardiac arrest, withdrawal of consent for medical data use